BRCA2

QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applications

Retrieved on: 
Jeudi, mai 30, 2024
NGS, Partnership, Patient, DNA, CDX, PMDA, Ovarian cancer, Myriad Genetics, QGEN, Clinical trial, MYGN, BRCA2, FDA, Neoplasm, Senior, Research, PMA, GIS, Cancer, Genetics, IP, Biomarker, BRCA1, QIAGEN, Innovation, AstraZeneca, HRD

Next-generation-sequencing-based homologous recombination deficiency (HRD) assay based on QIAGEN’s QIAseq xHYB technology, QIAGEN Digital Insight solutions, and Myriad’s proprietary, FDA-approved MyChoice CDx® biomarkers

Key Points: 
  • Next-generation-sequencing-based homologous recombination deficiency (HRD) assay based on QIAGEN’s QIAseq xHYB technology, QIAGEN Digital Insight solutions, and Myriad’s proprietary, FDA-approved MyChoice CDx® biomarkers
    VENLO, The Netherlands and SALT LAKE CITY, May 30, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Myriad Genetics (NASDAQ: MYGN) today announced they will develop a globally distributable kit-based test for analyzing Homologous Recombination Deficiency (HRD) status.
  • The project builds on the recently announced master collaboration agreement between the two companies.
  • “Our partnership with Myriad Genetics underscores a shared commitment to advancing cancer diagnostics.
  • The combined regulatory expertise of QIAGEN and Myriad enables seamless compliance and integration in clinical and companion diagnostic applications.

QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applications

Retrieved on: 
Jeudi, mai 30, 2024
NGS, Partnership, Patient, DNA, CDX, PMDA, Ovarian cancer, Myriad Genetics, QGEN, Clinical trial, MYGN, BRCA2, FDA, Neoplasm, LOH, Senior, Research, PMA, GIS, Cancer, Genetics, IP, BRCA1, QIAGEN, Innovation, AstraZeneca, HRD

Venlo, the Netherlands, and Salt Lake City, Utah, May 30, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Myriad Genetics (NASDAQ: MYGN) today announced they will develop a globally distributable kit-based test for analyzing Homologous Recombination Deficiency (HRD) status.

Key Points: 
  • Venlo, the Netherlands, and Salt Lake City, Utah, May 30, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Myriad Genetics (NASDAQ: MYGN) today announced they will develop a globally distributable kit-based test for analyzing Homologous Recombination Deficiency (HRD) status.
  • “Our partnership with Myriad Genetics underscores a shared commitment to advancing cancer diagnostics.
  • The IP license grants QIAGEN the capability to collaborate with pharmaceutical partners to create an IVD-validated test, intended for use as a companion diagnostic outside of the United States.
  • The combined regulatory expertise of QIAGEN and Myriad enables seamless compliance and integration in clinical and companion diagnostic applications.

Inocras Presents Poster for Breast Cancer at 2024 ASCO Annual Meeting, Showing Transformative Impact of WGS-based HRD Testing

Retrieved on: 
Samedi, juin 1, 2024
Oncology, Data Management, Health, Technology, Health Technology, Genetics, Biotechnology, Patient, ADP, Breast MRI, Inc., BRCA2, MRI, Breast cancer, Whole genome sequencing, Samsung Medical Center, MRD, WGS, Research, Breast, Cancer, Medicine, Biomarker, ASCO, Gene, BRCA1, Hospital, Woman, Society, DCE, Multimedia, HRD, Annual general meeting, Medical imaging

View the full release here: https://www.businesswire.com/news/home/20240531817764/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240531817764/en/
    In collaboration with Samsung Medical Center and St. Mary’s Hospital, Inocras' research study recruited 145 women with invasive breast cancer.
  • Researchers utilized dynamic contrast-enhanced (DCE) breast MRI to explore the relationship between HRD and specific radiomic features.
  • HRD, a crucial target in breast cancer treatment, involves key genes known as BRCA1 and BRCA2, whose pathogenic mutations are crucial features for selecting poly (ADP-ribose) polymerase inhibitors (PARPi) treatment.
  • “This research underscores the transformative impact of WGS-based HRD testing, allowing for a more comprehensive view of HRD and the development of better evaluation and screening tools,” said Inocras co-founder Jeong Seok Lee.

Mahdi Taha, DO, FACOI, FACP is Lead Author of Case Study Demonstrating Importance of Genomic Testing in Early identification and Treatment of Cancer

Retrieved on: 
Mardi, mai 7, 2024
Cancer, Mutation, FCS, Risk, Woman, Survival, APRN, Male, PSA, Research, BRCA2, NGS, Prostate cancer, Medicine, Patient, FACP, Breast cancer, Overalls, Gene, BRCA1, Medical imaging

FORT MYERS, Fla., May 7, 2024 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) medical oncologist and hematologist Mahdi Taha, DO, FACOI, FACP is lead author and Kayla Haines, APRN is co-author of a case study published in JCO® Precision Oncology detailing the importance of genomic testing in identifying cancer and guiding targeted treatment decisions that enhance overall survival, with a focus on metastatic prostate cancer.

Key Points: 
  • Inherited genetic mutations are known to increase risk for many forms of cancer in women and men.
  • Specifically, mutations in the breast cancer genes (known as BRCA1 and BRCA2) are the cause of aggressive forms of prostate cancer, the second most common cancer diagnosed in American men.
  • The article details the case of an 85-year-old male patient who presented to FCS for evaluation and treatment for metastatic prostate cancer with a rising PSA.
  • "Had genomic testing never been done on our patient, the BRCA2 mutation would have been unknown to the daughter," added Dr. Taha.

Accent Therapeutics Presents Data Supporting Two Lead Programs at AACR 2024 Annual Meeting

Retrieved on: 
Lundi, avril 8, 2024
BRCA, DNA repair, Mitosis, Apoptosis, Breast, PD, RME, Patient, DHX9, Neoplasm, Data, RNA, DNA, Cancer, Accent, Enzyme, AACR, Therapy, Breast cancer, BRCA2, Pharmaceutical industry

LEXINGTON, Mass., April 8, 2024 /PRNewswire/ -- Accent Therapeutics, a biopharmaceutical company pioneering a novel class of small molecule precision cancer therapeutics presents advances in cancer targeting, including data on DHX9 and KIF18A inhibitor activity in multiple tumor types, at the 2024 American Association for Cancer Research (AACR) Annual Meeting, taking place April 5-10 in San Diego, California.

Key Points: 
  • "Accent has expanded the potential of our two lead programs in preclinical investigations, and we are excited for the promise they hold for addressing cancers with high unmet clinical need," said Robert A. Copeland, Ph.D., President, Founder, and Chief Scientific Officer of Accent Therapeutics.
  • "Our results reveal that DHX9 and KIF18A inhibition are potent therapeutic strategies that stand to benefit large patient populations.
  • These findings validate our systematic approach to tapping the rich therapeutic potential of our target space."
  • These data are highlighted in a presentation entitled "DHX9 inhibition as a novel therapeutic for cancer with loss-of-function mutations in DNA damage repair genes BRCA1 and BRCA2."

Bionano Announces Publication of a Breast Cancer Study Showing that the Number of SVs Detected with OGM May Be Related to Prognosis, Tumor Progression and Chemotherapy Resistance

Retrieved on: 
Mardi, mars 19, 2024
Ovarian cancer, DNA repair, Breast, SAN, Neoplasm, DNA, HBOC, Doctor of Philosophy, Medicine, Genomics, Chromothripsis, SVS, Breast cancer, HRD, BRCA2, OGM, BRCA1, Drug resistance, Medical imaging

HBOC syndrome is estimated to cause 5-10% of all breast cancers and is commonly characterized by harmful germline mutations in the BRCA1 or BRCA2 genes.

Key Points: 
  • HBOC syndrome is estimated to cause 5-10% of all breast cancers and is commonly characterized by harmful germline mutations in the BRCA1 or BRCA2 genes.
  • The study authors selected OGM for this analysis due to its ability to detect multiple classes of SVs with genome-wide coverage, high resolution and accuracy.
  • Eight novel gene fusions were identified by OGM, including three that had not previously been detected by other methods of analysis.
  • “We are pleased to see the publication of this study, which highlights OGM as a promising tool for detecting novel variants in HBOC-related breast cancer that have oncogenic potential.

Nucleus Genomics launches to bring whole-genome sequencing to the public

Retrieved on: 
Lundi, mars 25, 2024
Technology, Research, Medical Devices, Genetics, Biotechnology, Health, Pharmaceutical, Science, Consumer Electronics, Human Genome Project, WGS, Blood pressure, Genomics, Certification, Informatics, Genetic testing, Nucleus, Risk, Human, PRS, DNA, Accreditation, Breast, CAP, Overalls, Facial muscles, Cancer, CLIA, Breast cancer, BRCA2, BMI, BRCA1, Vaccine

Nucleus Genomics , the next-generation genetic testing and analysis company, today announced the launch of its DNA analysis product to bring the benefits of personalized medicine to everyone.

Key Points: 
  • Nucleus Genomics , the next-generation genetic testing and analysis company, today announced the launch of its DNA analysis product to bring the benefits of personalized medicine to everyone.
  • Nucleus will also offer pre-orders for its premium clinical-grade whole-genome sequencing (WGS) service, in which a customer’s entire set of DNA will be read and analyzed.
  • Nucleus is proud to sequence all customer samples in the U.S. on Illumina’s NovaSeq X Plus, the sequencing company’s newest and most innovative high-throughput sequencing instrument.
  • Working with Illumina, Nucleus is leveraging this latest sequencing technology to make WGS broadly accessible to power personalized healthcare.

INTERACT COALITION FORMED TO ADVANCE PATIENT ACCESS TO GENETIC TESTING FOR HEREDITARY CANCER RISK

Retrieved on: 
Mercredi, avril 3, 2024
Ovarian cancer, Quest Diagnostics, Gene, Mutation, Genetic testing, Chemoprophylaxis, Incidence, Risk, Genetics, Education, SAN, Patient, Policy, Cancer, Hereditary nonpolyposis colorectal cancer, Salpingo-oophorectomy, Mastectomy, Breast cancer, Therapy, BRCA2, Physician, BRCA1, Cancer syndrome, Human, Vaccine

The coalition seeks to provide a collective voice in support of the progression of medical professional and industry guidelines for genetic testing for inherited mutations that increase cancer risk.

Key Points: 
  • The coalition seeks to provide a collective voice in support of the progression of medical professional and industry guidelines for genetic testing for inherited mutations that increase cancer risk.
  • With growing insight into the role of genetic testing in cancer risk management and treatment, the population of individuals who benefit from knowing their genetic mutation status continues to increase.
  • Hereditary cancer genetic testing has been shown to improve outcomes by identifying those most at risk and informing management strategies.
  • Among the challenges to broadening access to genetic testing for hereditary cancer risk is a time lag in updating guidelines and medical policies after the publication of new medical literature.

Nucleus Genomics launches to bring whole-genome sequencing to the public

Retrieved on: 
Lundi, mars 25, 2024
Human Genome Project, WGS, Blood pressure, Genomics, Health, Certification, Informatics, Founders Fund, Genetic testing, Risk, Genetics, Human, PRS, DNA, Accreditation, Breast, CAP, Overalls, Facial muscles, Cancer, CLIA, Breast cancer, BRCA2, BMI, BRCA1

NEW YORK, March 25, 2024 /PRNewswire/ -- Nucleus Genomics, the next-generation genetic testing and analysis company, today announced the launch of its DNA analysis product to bring the benefits of personalized medicine to everyone.

Key Points: 
  • Nucleus further personalizes these risk assessments by integrating personal and lifestyle factors into their analysis — such as age, cholesterol levels, blood pressure, and BMI.
  • Nucleus will also offer pre-orders for its premium clinical-grade whole-genome sequencing (WGS) service, in which a customer's entire set of DNA will be read and analyzed.
  • Nucleus is proud to sequence all customer samples in the U.S. on Illumina's NovaSeq X Plus, the sequencing company's newest and most innovative high-throughput sequencing instrument.
  • Working with Illumina, Nucleus is leveraging this latest sequencing technology to make WGS broadly accessible to power personalized healthcare.

Labcorp Presents New Research Demonstrating Clinical Impact of Precision Diagnostics in Guiding Biomarker-targeted Therapies for Patients with Epithelial Ovarian Cancer

Retrieved on: 
Samedi, mars 16, 2024
Diagnosis, Ovarian cancer, MIRV, Mutation, Health, BRCA, Science, Disease, Partnership, Patient, Education, Glomus tumor, Roche, Biomarker, Neoplasm, Research, Cancer, EOC, Recombinant DNA, Woman, HRP, PARP, TTD, Fibroadenoma, HRD, Mirvetuximab soravtansine, BRCA2, Recurrence, LH, BRCA1, ADP, Pharmaceutical industry

BURLINGTON, N.C., March 16, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today presented the results from two studies at the 2024 SGO Annual Meeting on Women's Cancer. The studies demonstrate the value of biomarker testing in closing testing gaps and guiding targeted therapies for patients with epithelial ovarian cancer (EOC).

Key Points: 
  • The studies demonstrate the value of biomarker testing in closing testing gaps and guiding targeted therapies for patients with epithelial ovarian cancer (EOC).
  • Labcorp researchers conducted two studies to generate further evidence of the value of comprehensive genomic profiling to drive guideline-compliant testing that enables increased patient access to targeted therapies for improved outcomes.
  • When combined, the results of BRCA and HRD testing can determine which patients are most likely to benefit from treatment with poly-ADP ribose polymerase (PARP) inhibitors.
  • "This research emphasizes the power of comprehensive biomarker testing in advancing the treatment of ovarian cancer.